Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Temozolomide/Lomustine (TMZ/LOM) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT Promoter Methylated Glioblastoma (IDHwt) Patients +/- Tumor Treating Fields (Optune)

NCT06419946 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT06419946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06419946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Temozolomide/Lomustine (TMZ/LOM) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT Promoter Methylated Glioblastoma (IDHwt) Patients +/- Tumor Treating Fields (Optune)
Lead sponsor
Vastra Gotaland Region
Phase
Phase 3
Overall status
Recruiting
Start date
February 1, 2025
Completion date
December 15, 2033
Enrollment
200 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, idh-wildtype, mgmt-methylated glioblastoma